Fulcrum Historical Cash Flow
| FULC Stock | USD 3.44 0.19 5.85% |
Analysis of Fulcrum Therapeutics cash flow over time is an excellent tool to project Fulcrum Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 8.5 M or Begin Period Cash Flow of 48.3 M as it is a great indicator of Fulcrum Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Fulcrum Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Fulcrum Therapeutics is a good buy for the upcoming year.
Fulcrum |
About Fulcrum Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Fulcrum balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Fulcrum's non-liquid assets can be easily converted into cash.
Fulcrum Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Fulcrum Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Fulcrum Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Fulcrum Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Fulcrum Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.At present, Fulcrum Therapeutics' Change Receivables is projected to increase significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 48.3 M, whereas Sale Purchase Of Stock is projected to grow to (165 K).
Fulcrum Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Fulcrum Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fulcrum Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | 105.1M | (34K) | (193K) | 3.7M | (173.7K) | (165.0K) | |
| Investments | (944K) | (55.8M) | (128.0M) | 14.4M | (91.4M) | (86.8M) | |
| Change In Cash | 23.9M | (39.7M) | (21.6M) | (314K) | (9.5M) | (9.1M) | |
| Stock Based Compensation | 4.2M | 7.4M | 11.1M | 13.4M | 14.8M | 8.5M | |
| Free Cash Flow | (40.3M) | (55.0M) | (80.2M) | (99.0M) | (91.5M) | (96.0M) | |
| Change In Working Capital | 11.3M | 7.5M | (11.9M) | (3.1M) | (4.6M) | (4.4M) | |
| Begin Period Cash Flow | 73.9M | 97.8M | 58.1M | 36.5M | 36.2M | 48.3M | |
| Total Cashflows From Investing Activities | (944K) | (57.1M) | (129.7M) | 12.4M | 11.2M | 11.7M | |
| Other Cashflows From Financing Activities | 249K | 69.9M | 3.7M | 3.5M | 777K | 738.2K | |
| Depreciation | 2.1M | 2.4M | 2.5M | 2.4M | 2.2M | 2.1M | |
| Capital Expenditures | 853K | 1.3M | 1.7M | 2.0M | 508K | 482.6K | |
| Total Cash From Operating Activities | (39.5M) | (53.7M) | (78.5M) | (97.1M) | (91.0M) | (95.5M) | |
| Change To Operating Activities | 523K | 380K | 1.4M | (1.5M) | (1.4M) | (1.3M) | |
| Net Income | (82.7M) | (70.8M) | (80.8M) | (109.9M) | (97.3M) | (102.2M) | |
| Total Cash From Financing Activities | 64.3M | 71.1M | 186.5M | 84.3M | 118.1M | 101.7M | |
| End Period Cash Flow | 97.8M | 58.1M | 36.5M | 36.2M | 26.7M | 37.7M | |
| Change To Netincome | 29.8M | 7.4M | 11.1M | 13.4M | 15.4M | 11.9M | |
| Change To Liabilities | 10.8M | 11.6M | (10.2M) | (4.4M) | (4.0M) | (3.8M) | |
| Other Non Cash Items | 25.6M | (2M) | 673K | 152K | (6.0M) | (6.3M) | |
| Issuance Of Capital Stock | 64.2M | 69.9M | 182.9M | 80.8M | 117.3M | 113.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fulcrum Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fulcrum Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fulcrum Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fulcrum Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 1.317 | Quarterly Revenue Growth 89.909 | Return On Assets (0.07) | Return On Equity (0.07) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.